FRM
AQST icon

Fox Run Management’s Aquestive Therapeutics AQST Stock Holding History

Fox Run Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-34,518
Closed -$223K – 896
2025
Q4 		$223K Buy
+34,518
New +$215K 0.03% 774

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fox Run Management's AQST Position: Q1 2026 in Review

Fox Run Management sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 34,518 shares — an estimated $223K sold.

Fox Run Management first reported a position in AQST in Q4 2025 and held it in 1 quarter. The position peaked at $223K in Q4 2025. 180 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Fox Run Management reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 34,518 Aquestive Therapeutics shares in Q1 2026, an estimated $223K.
  • Fox Run Management first reported a position in Aquestive Therapeutics in Q4 2025 and held it in 1 quarter.
  • Fox Run Management's Aquestive Therapeutics position peaked at $223K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.